Get notified when VYNE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Yarrow, the company VYNE plans to merge with, has substantial doubt about its ability to continue as a going concern without additional funding.
- Material Weakness (new) — The filing discloses a risk that the Combined Company could face material weaknesses in internal control over financial reporting.
- Dilution (new) — Existing VYNE stockholders will be diluted to approximately 3% ownership in the combined company.
- Product Failure (new) — VYNE's lead product candidate failed its Phase 2b trial, and another candidate is under a partial clinical hold.
- Liquidation Risk (new) — If the merger fails, VYNE's board may pursue dissolution and liquidation, potentially leaving stockholders with little or no value.
VYNE Therapeutics to merge with Yarrow Bio, leaving VYNE holders with ~3% of combined company
Filed June 15, 2026 · ~2 min read
Key Changes
-
high
VYNE and Yarrow propose a reverse triangular merger; Yarrow becomes a wholly owned subsidiary of VYNE, with Yarrow shares converting into VYNE common stock and/or pre-funded warrants at an exchange ratio detailed on page 173.
The Offering verify on EDGAR → -
high
Post-merger, VYNE securityholders are expected to own only ~3.0% of the combined company on a fully-diluted basis, while Yarrow securityholders own ~97.0%.
Prospectus Summary verify on EDGAR → -
high
VYNE expects to pay a pre-closing cash dividend of approximately $14.5 million to $16.5 million to its stockholders.
Prospectus Summary verify on EDGAR →
7 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade VYNE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify